Roivant Sciences
ROIV
34.75
-0.78
-2.20%
Roivant Sciences
US · ROIV
#747 by market cap
Listed 1970
34.75
-0.78
-2.20%
Live - 5344 symbols - heartbeat 210s ago
· 2026-10-08 07:00
Pre-market
34.00
-2.16%
After-hours
35.06
+0.91%
Overnight
34.55
-0.58%
- Market cap
- 25.10B
- P/E (TTM)i
- -73.94
- P/Bi
- 5.93
- EPSi
- -0.54
- Div yieldi
- 0.00%
- 52W posi
- 71%
Reader sentiment
Are you bullish or bearish on ROIV?
Anonymous reader poll. Unscientific, not investment advice.
About Roivant Sciences
Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. Its product portfolio includes Vtama, Batoclimab, Brepocitinib, Namilumab, and RVT-2001, which aims to treat psoriasis, atopic dermatitis, thyroid eye disease, and other illnesses. The company was founded by Vivek Ramaswamy on April 7, 2014 and is headquartered in London, the United Kingdom.
- Founded
- 2021
- CEO
- Mr. Matthew Gline
- Employees
- 721
- Headquarters
- London, Greater London, United Kingdom of Great Britain and Northern Ireland (the)
- Fiscal year end
- 03-31
- Website
- roivant.com
Company profile
- Exchange
- US
- Symbol
- ROIV
- Market-cap rank
- #747
- Listing date
- 1970-01-01
- Market cap
- 25.10B
- Float cap
- 20.22B
- Shares out
- 722.32M
- Float shares
- 581.94M
Sectors & themes
Biotechnology
Fractional Shares JP
Quote time 2026-10-08 07:00:11 · For reference only, not investment advice and not tailored to your situation.